Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort

Background We aimed to investigate the efficacy of postoperative adjuvant transarterial chemoembolisation (PA‐TACE) in patients with hepatocellular carcinoma (HCC) complicated by microvascular invasion (MVI). Methods A retrospective analysis of 1505 patients with HCC who underwent hepatectomy at fou...

Full description

Saved in:
Bibliographic Details
Published in:United European gastroenterology journal 2023-03, Vol.11 (2), p.228-241
Main Authors: Luo, Laihui, Shan, Renfeng, Cui, Lifeng, Wu, Zhao, Qian, Junlin, Tu, Shuju, Zhang, WenJian, Xiong, Yuanpeng, Lin, Wei, Tang, Hongtao, Zhang, Yang, Zhu, Jisheng, Huang, Zeyu, Li, Zhigang, Mao, Shengping, Li, Hui, Hu, Zemin, Peng, Peng, He, Kun, Li, Yong, Liu, Liping, Shen, Wei, He, Yongzhu
Format: Article
Language:English
Subjects:
Ablation
adjuvant
Cancer therapies
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Catheters
Chemoembolization
Chemoembolization, Therapeutic - adverse effects
Chemoembolization, Therapeutic - methods
Creatinine
HCC
Hepatectomy
hepatocellular carcinoma
Hepatology
Hospitals
Humans
Liver cancer
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver transplants
Magnetic resonance imaging
Medical prognosis
Medical technology
Metastasis
microvascular invasion
Multiple organ dysfunction syndrome
Normal distribution
Original
Patients
propensity score
Retrospective Studies
Software
survival
Survival analysis
TACE
transarterial chemoembolisation
Treatment Outcome
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We aimed to investigate the efficacy of postoperative adjuvant transarterial chemoembolisation (PA‐TACE) in patients with hepatocellular carcinoma (HCC) complicated by microvascular invasion (MVI). Methods A retrospective analysis of 1505 patients with HCC who underwent hepatectomy at four medical centers, including 782 patients who received PA‐TACE and 723 patients who did not receive adjuvant PA‐TACE, has been conducted. Propensity score matching (PSM) (1:1) was performed on the data to minimise selection bias, which resulted in a balanced clinical profile between groups. Results After PSM, 620 patients who received PA‐TACE and 620 patients who did not receive PA‐TACE were included. Disease‐free survival (DFS, 1‐, 2‐, and 3‐year: 88%‐68%‐61% vs. 70%‐58%‐51%, p 
ISSN:2050-6406
2050-6414
DOI:10.1002/ueg2.12365